NCT03611738View on ClinicalTrials.gov

Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

February 1, 2019

Primary Completion Date

April 28, 2025

Study Completion Date

April 30, 2026

Conditions
Non-small Cell Lung CancerLung CancerNon-small Cell Lung Cancer MetastaticNon-small Cell Lung Cancer Stage IIIBStage IV Non-small Cell Lung CancerEGFR Negative Non-Small Cell Lung Cancer
Interventions
DRUG

Ceritinib

Ceritinib daily by mouth (PO) with food, according to the dosage schedule outlined in the treatment arm.

DRUG

Docetaxel

Docetaxel intravenously (IV) every 3 weeks, according to the dosage schedule outlined in the treatment arm.

Trial Locations (2)

32804

Advent Health Orlando, Orlando

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

All Listed Sponsors
lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER